IKT inhibikase.com: Buxgalteriya kapitallashuvi

Inhibikase Therapeutics, Inc. (IKT) - korporativ logo

Inhibikase Therapeutics (IKT) demensiya tadqiqotlari uchun biomateriallarning aniq transportini tashkil etadi, அதே vaqtda noyob Altsgeymer kasalligi davolash vositalarining ishlab chiqilishi kompaniyaga dominant narx belgilash imkoniyatini beradi. Ushbu narxlar grafigi ko'rsatkichni 0.15 darajasida qayd etdi. Hozirgi vaqtda kinaza inhibitorlari tadqiqot markazlari to'liq quvvatda ishlamoqda, sterillashgan xonalar va xromatografik uskunalar muntazam ravishda modernizatsiya qilinmoqda.

Inhibikase (IKT): Kompaniyaning sof aktivlari 04.07.2022dan 30.10.2026gacha

IKT (Inhibikase Therapeutics, Inc.): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- aksiya narxi va konsensus maqsadli narx:
Narx Inhibikase Pharma|IKT - Maqsadli narxlar grafigi
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
Bozor kapitallashuvi Inhibikase Therapeutics Inc|IKT - Korxona qiymati
- balans kapitallashuvi ko'rsatkichlari:
Bitta aksiya hisobiga sof aktivlar qiymati Inhibikase Therapeutics|IKT - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga nisbati inhibikase.com|IKT - Kompaniyaning jami aktivlari
- kompaniyaning jami qarzi va likvidligi ko'rsatkichlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Inhibikase Therapeutics|IKT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Inhibikase Therapeutics Inc|IKT - Kompaniyaning jamlangan qarzlari|Sof aktivlarga qarzlar Inhibikase Therapeutics Inc|IKT - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Inhibikase Therapeutics|Oraliq qoplash koeffitsiyenti inhibikase.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
IKT - Sof foyda
Kompaniyaning fundamental baholanishi:IKT (Inhibikase Pharma)
Inhibikase Therapeutics tovar namunasi

Kitalik qiymat kapitalizatsiyasi Inhibikase Therapeutics (IKT) sof aktivlarining bozor spekulyatsiyalarini hisobga olmagan holda real qiymatini aks ettiradi. Ushbu metrikani tahlil qilish biznesning fundamental barqarorligini va aksiyalarning haddan tashqari qimmat baholanishi xavfini baholash imkonini beradi. Kitalik qiymat kapitalizatsiyasi moliyaviy ko'rsatkichi birja kursi va haqiqiy kapital o'rtasidagi farqni ochib beradi. Inhibikase Therapeutics (IKT) uchun ushbu metrika 2-bosqich klinik sinovlar natijalari kutilayotgan vaqtda hal qiluvchi ahamiyatga ega. Parkinson kasalligi terapiyasining muvaffaqiyati aktivlarning ichki qiymatini keskin o'zgartirishi mumkin.

Raqobatchilar tahlili

Biogen Idec - Jami sof aktivlar|Neurocrine Biosciences (NBIX) - Kompaniyaning balans qiymati|Buxgalteriya kapitallashuvi RGC|AXSM (Axsome Therapeutics, Inc.) - Balans kapitallashuvi|Kompaniyaning xususiy kapitali ACADIA Pharma ACAD|Kompaniyaning sof aktivlari XENE (Xenon Pharmaceuticals Inc)|Balans kapitallashuvi Viking Therapeutics Corp (VKTX)|Kompaniyaning balans qiymati Supernus Pharmaceuticals SUPN|Kompaniyaning buxgalteriya qiymati CPRX|DNLI - Kompaniyaning balans qiymati|Kompaniyaning xususiy kapitali Harmony Biosciences Inc|BHVN: Balans kapitallashuvi|AMLX - Biznesning balans bahosi|Kompaniyaning balans qiymati Trevi Therapeutics|Buxgalteriya kapitallashuvi PRAX (praxismedicines.com)|Balans kapitallashuvi AVXL|CBLL (CeriBell Inc) - Kompaniyaning buxgalteriya qiymati|Balans kapitallashuvi PRTA (prothena.com)|Biznesning balans bahosi Alector Inc. (ALEC)|Annexon, Inc. - Balans kapitallashuvi|OMER: Kompaniyaning balans qiymati|NGNE: Balans kapitallashuvi|ACIU - Biznesning balans bahosi|Kompaniyaning balans qiymati Voyager Pharma|Balans kapitallashuvi Neumora Corp|Balans kapitallashuvi SCLX|Balans kapitallashuvi tevogen.com (TVGN)|Kompaniyaning balans qiymati Alpha Cognition Inc. ACOG|Biznesning balans bahosi cogrx.com (CGTX)|Cassava - Balans kapitallashuvi|Kompaniyaning xususiy kapitali Assertio Holdings, Inc.|COYA (coyatherapeutics.com) - Kompaniyaning sof aktivlari|Vistagen - Kompaniyaning buxgalteriya qiymati|Kompaniyaning sof aktivlari OVID|ABOS (Acumen Pharmaceuticals Inc.) - Jami sof aktivlar|Balans kapitallashuvi CRVO|ATHE (alteritytherapeutics.com) - Kompaniyaning buxgalteriya qiymati|Balans kapitallashuvi CLNN (Clene)|PepGen Inc (PEPG) - Kompaniyaning xususiy kapitali|JUNS - Kompaniyaning balans qiymati|Kompaniyaning buxgalteriya qiymati RLMD (Relmada Therapeutics Inc)|ANVS: Balans kapitallashuvi|Grace Therapeutics (GRCE) - Balans kapitallashuvi|Kompaniyaning balans qiymati Firefly Neuroscience, Inc|ANEW Medical, Inc. - Sof aktivlar qiymati|Balans kapitallashuvi NRSN|RVPH - Kompaniyaning xususiy kapitali|MetaVia - Kompaniyaning sof aktivlari|Balans kapitallashuvi NeurAxis Inc NRXS|HSDT: Kompaniyaning sof aktivlari|Passage Bio, Inc. - Jami sof aktivlar|NEUP: Balans kapitallashuvi|NERV - Biznesning balans bahosi|ATHA (Athira) - Balans kapitallashuvi|Kompaniyaning sof aktivlari Addex (ADXN)|Kompaniyaning balans qiymati Alzamend Neuro, Inc. (ALZN)|Biznesning balans bahosi cyclerion.com|Balans kapitallashuvi PTIX (Protagenic Therapeutics, Inc.)|Biznesning balans bahosi Pasithea Therapeutics Corp (KTTA)|CRGT - Kompaniyaning balans qiymati|ATXI - Balans kapitallashuvi|BCLI (Brainstorm Cell) - Kompaniyaning sof aktivlari|CARA: Jami sof aktivlar|Kompaniyaning balans qiymati Chromocell Therapeutics Corp.|Buxgalteriya kapitallashuvi ELYM (Eliem)|Balans kapitallashuvi ITCI|LBPH - Kompaniyaning xususiy kapitali|Marinus Pharmaceuticals - Kompaniyaning sof aktivlari|Balans kapitallashuvi nkgenbiotech.com NKGN|NRBO - Kompaniyaning balans qiymati|Kompaniyaning buxgalteriya qiymati SAGE (Sage Therapeutics Inc.)|Neurotrope (SNPX) - Kompaniyaning balans qiymati|Kompaniyaning xususiy kapitali Trevena Inc (TRVN)|VIGL (Vigil Neuroscience Inc.) - Balans kapitallashuvi|Anew Medical Inc. (WENA) - Biznesning balans bahosi|Kompaniyaning balans qiymati Cerevel Therapeutics, Inc. (CERE)